Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Dec
15
Today In Oncology
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Menopausal Hormone Therapy Not Associated With Increased Breast Cancer Risk
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications
FDA Approves Regimen for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo